Navigating uncertainty in life sciences
November 3, 2026 | Pharma, healthcare
The life sciences industry is changing fast. Advances in AI, increasingly complex science, shifting market dynamics and evolving patient needs are creating new challenges for organizations developing and commercializing treatments. For leaders, the question is not simply how to respond to change, but how to stay ahead of it.
In a recent interview with Consultancy.uk, Remco op den Kelder, Group President at Inizio Ignite, shares his perspective on the forces reshaping the industry and what organizations need to do differently to succeed.
One of the biggest challenges is fragmentation. As commercialization becomes more complex, teams across strategy, medical affairs, market access and commercial functions need to work together more effectively. Remco explores why connecting people, insights and decisions is becoming increasingly important, and how organizations can build the flexibility to respond as circumstances change.
The conversation also looks at the role of AI. Rather than technology for technology’s sake, the opportunity is to combine AI with human expertise to spot emerging trends, learn from real-time insights and make better, faster decisions.
Read the full article here.
This content was provided by Inizio
Company Details
Latest Content from Inizio
How pharma companies can use AI to scale personalized engagement without increasing complexity
AI is creating a world of opportunities for pharma companies to deliver more personalized HCP and patient engagement. But realizing the full potential of AI takes more than just introducing…
Creating the conditions for product launch success in a time of volatility
Volatility is reshaping the conditions for successful product launches. Market dynamics can shift quickly, assumptions can change, and teams are increasingly expected to make confident decisions in response.
Navigating uncertainty in life sciences
The life sciences industry is changing fast. Advances in AI, increasingly complex science, shifting market dynamics and evolving patient needs are creating new challenges for organizations developing and commercializing treatments….
Inizio appoints Oisín Ó Gógáin as Chief People Officer
Inizio has appointed Oisín Ó Gógáin as Chief People Officer.
Pharma leadership strategies for talent, AI adoption, and continuous learning
In a recent interview with Pharma Exec, Elaine Ferguson, Global President of Inizio Medical, explores how pharma leadership can support talent development, use AI to augment the workforce, encourage continuous…
Smarter science, sharper strategy: Expert insights from ASCO® 2026
As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?
Intelligent Commercialization™ across the pharma lifecycle
Pharma teams are under growing pressure to navigate launch complexity, identify risks earlier, and engage HCPs more effectively.
Four steps to a smarter congress strategy: A practical guidebook
This guidebook explores how Intelligent Congress helps pharma teams create more coordinated, measurable, and impactful congress strategies.
Infographic: Are data blind spots putting your launch at risk?
Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize…
Key takeaways from ASCO® 2026
Following ASCO® 2026, Inizio’s experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year’s congress revealed for pharmaceutical organisations. Together, they…